Year-end Sale % OFF 
Abstract
It is widely believed that dyslipidaemia related to the duration of highly active antiretroviral therapy (HAART) contributes most to an increased predicted risk of cardiovascular disease (CVD) among patients with HIV. Consequently, it is increasingly suggested that hypercholesterolemia should be actively managed with the use of lipid-lowering drugs. However, when studying the impact of individual antiretroviral drugs on the risk of coronary heart disease in HIV-infected patients, it has been shown that the risk of myocardial infarction is only partly mediated by an effect of HAART on lipid metabolism [ [1] Lang S. Mary-Krause M. Cotte L. Clinical Epidemiology Group of the French Hospital Database on HIV et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case–control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med. 2010; 170: 1228-1238 Crossref PubMed Scopus (264) Google Scholar ]. Furthermore, in this setting, hypercholesterolemia may represent a blessing in disguise.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
